Login to Your Account

BLA for Pharming's, Santarus' HAE Drug Refused by FDA

By Nuala Moran

Wednesday, March 2, 2011
LONDON – The FDA issued a refusal to file notice to Pharming NV and its partner Santarus Inc., for Rhucin, a recombinant protein product for treating hereditary angioedema (HAE), which is generated in the milk of transgenic rabbits. (BioWorld International)

To continue reading subscribe now to BioWorld Asia (formerly International)

Learn More about BioWorld Asia (formerly International)

Already a subscriber? Sign In or Buy now to activate your subscription